Literature DB >> 24674041

Effect of progestins on immunity: medroxyprogesterone but not norethisterone or levonorgestrel suppresses the function of T cells and pDCs.

Richard P H Huijbregts1, Katherine G Michel1, Zdenek Hel2.   

Abstract

OBJECTIVES: The potential effect of hormonal contraception on HIV-1 acquisition and transmission represents an important public health issue. Several observational studies have suggested an association between the use of hormonal contraception, in particular injectable depot medroxyprogesterone acetate (DMPA), and an increased risk of HIV-1 acquisition and transmission. We and others have previously demonstrated that DMPA acts as a potent inhibitor of innate and adaptive immune mechanisms. The study presented here addresses the immunomodulatory properties of several common progestins with a potential to replace DMPA. STUDY
DESIGN: To identify safe alternatives to DMPA, we tested the effect of commonly used progestins on the function of human primary T cells and plasmacytoid dendritic cells (pDCs) obtained from the blood of healthy premenopausal women.
RESULTS: Medroxyprogesterone acetate (MPA) inhibited the activation of T cells and pDCs in response to T cell receptor- and Toll-like receptor-mediated activation at physiological concentrations. Etonogestrel exerted a partial suppressive activity at high concentrations. In sharp contrast, norethisterone (NET) and levonorgestrel (LNG) did not exhibit detectable immunosuppressive activity.
CONCLUSION: Evidence indicating the immunosuppressive properties of DMPA strongly suggests that DMPA should be discontinued and replaced with other forms of long-term contraception. Since NET and LNG do not exert immunosuppressive properties at physiological concentrations, these progestins should be considered as alternative contraceptives for women at high risk for HIV-1 infection. IMPLICATIONS: The presented data suggest that, at physiological levels, the progestins NET and LNG do not suppress cytokine production by immune cells and should be considered as alternatives to DMPA; however, more in vivo testing is needed to confirm this data.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AIDS; DMPA; ETG; HIV-1; Hormonal contraception; LNG; NET; Progestins

Mesh:

Substances:

Year:  2014        PMID: 24674041      PMCID: PMC4874781          DOI: 10.1016/j.contraception.2014.02.006

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  66 in total

Review 1.  The levonorgestrel intrauterine system: therapeutic aspects.

Authors:  T Luukkainen
Journal:  Steroids       Date:  2000 Oct-Nov       Impact factor: 2.668

Review 2.  Depot medroxyprogesterone versus norethisterone oenanthate for long-acting progestogenic contraception.

Authors:  B H Draper; C Morroni; M Hoffman; J Smit; M Beksinska; J Hapgood; L Van der Merwe
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

Review 3.  Glucocorticoids in T cell apoptosis and function.

Authors:  M J Herold; K G McPherson; H M Reichardt
Journal:  Cell Mol Life Sci       Date:  2006-01       Impact factor: 9.261

4.  Abrogation of attenuated lentivirus-induced protection in rhesus macaques by administration of depo-provera before intravaginal challenge with simian immunodeficiency virus mac239.

Authors:  Kristina Abel; Tracy Rourke; Ding Lu; Kristen Bost; Michael B McChesney; Christopher J Miller
Journal:  J Infect Dis       Date:  2004-09-24       Impact factor: 5.226

5.  Depo-Provera abrogates attenuated lentivirus-induced protection in male rhesus macaques challenged intravenously with pathogenic SIVmac239.

Authors:  Meritxell Genescà; Jun Li; Linda Fritts; Paul Chohan; Kristen Bost; Tracy Rourke; Shelley A Blozis; Michael B McChesney; Christopher J Miller
Journal:  J Med Primatol       Date:  2007-08       Impact factor: 0.667

6.  Binding of progestins to the glucocorticoid receptor. Correlation to their glucocorticoid-like effects on in vitro functions of human mononuclear leukocytes.

Authors:  K Kontula; T Paavonen; T Luukkainen; L C Andersson
Journal:  Biochem Pharmacol       Date:  1983-05-01       Impact factor: 5.858

7.  Medroxyprogesterone acetate inhibits CD8+ T cell viral-specific effector function and induces herpes simplex virus type 1 reactivation.

Authors:  Thomas L Cherpes; James L Busch; Brian S Sheridan; Stephen A K Harvey; Robert L Hendricks
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

8.  Dendritic cell activation and memory cell development are impaired among mice administered medroxyprogesterone acetate prior to mucosal herpes simplex virus type 1 infection.

Authors:  Rodolfo D Vicetti Miguel; Robert L Hendricks; Alfredo J Aguirre; Melissa A Melan; Stephen A K Harvey; Tracy Terry-Allison; Anthony J St Leger; Angus W Thomson; Thomas L Cherpes
Journal:  J Immunol       Date:  2012-08-31       Impact factor: 5.422

9.  Cutting edge: progesterone regulates IFN-alpha production by plasmacytoid dendritic cells.

Authors:  Grant C Hughes; Sunil Thomas; Chang Li; Murali-Krishna Kaja; Edward A Clark
Journal:  J Immunol       Date:  2008-02-15       Impact factor: 5.422

10.  Injectable progestin contraceptive use and risk of HIV infection in a South African family planning cohort.

Authors:  Immo Kleinschmidt; Helen Rees; Sinead Delany; Dawn Smith; Natalya Dinat; Busi Nkala; James A McIntyre
Journal:  Contraception       Date:  2007-04-05       Impact factor: 3.375

View more
  35 in total

Review 1.  Hormonal Contraception and HIV-1 Acquisition: Biological Mechanisms.

Authors:  Janet P Hapgood; Charu Kaushic; Zdenek Hel
Journal:  Endocr Rev       Date:  2018-02-01       Impact factor: 19.871

2.  Characterization of the Horizontal and Vertical Sexual Transmission of Chlamydia Genital Infections in a New Mouse Model.

Authors:  Sukumar Pal; Delia F Tifrea; Luis M de la Maza
Journal:  Infect Immun       Date:  2019-06-20       Impact factor: 3.441

3.  Medroxyprogesterone acetate impairs human dendritic cell activation and function.

Authors:  N E Quispe Calla; M G Ghonime; T L Cherpes; R D Vicetti Miguel
Journal:  Hum Reprod       Date:  2015-03-03       Impact factor: 6.918

4.  Plasma concentration of injectable contraceptive correlates with reduced cervicovaginal growth factor expression in South African women.

Authors:  Refilwe P Molatlhegi; Lenine J Liebenberg; Alasdair Leslie; Laura Noel-Romas; Amanda Mabhula; Nobuhle Mchunu; Michelle Perner; Kenzie Birse; Sinaye Ngcapu; John H Adamson; Katya Govender; Nigel J Garrett; Natasha Samsunder; Adam D Burgener; Salim S Abdool Karim; Quarraisha Abdool Karim; Jo-Ann S Passmore; Lyle R McKinnon
Journal:  Mucosal Immunol       Date:  2020-01-02       Impact factor: 7.313

5.  Association between injectable progestin-only contraceptives and HIV acquisition and HIV target cell frequency in the female genital tract in South African women: a prospective cohort study.

Authors:  Elizabeth H Byrne; Melis N Anahtar; Kathleen E Cohen; Amber Moodley; Nikita Padavattan; Nasreen Ismail; Brittany A Bowman; Gregory S Olson; Amanda Mabhula; Alasdair Leslie; Thumbi Ndung'u; Bruce D Walker; Musie S Ghebremichael; Krista L Dong; Douglas S Kwon
Journal:  Lancet Infect Dis       Date:  2015-12-24       Impact factor: 25.071

6.  Effect of hormonal contraception on the function of plasmacytoid dendritic cells and distribution of immune cell populations in the female reproductive tract.

Authors:  Katherine G Michel; Richard P H Huijbregts; Jonathan L Gleason; Holly E Richter; Zdenek Hel
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

7.  Levonorgestrel in contraceptives and multipurpose prevention technologies: does this progestin increase HIV risk or interact with antiretrovirals?

Authors:  Chelsea B Polis; Sharon J Phillips; Sharon L Hillier; Sharon L Achilles
Journal:  AIDS       Date:  2016-11-13       Impact factor: 4.177

Review 8.  Drug-Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV.

Authors:  Kimberly K Scarsi; Kristin M Darin; Catherine A Chappell; Stephanie M Nitz; Mohammed Lamorde
Journal:  Drug Saf       Date:  2016-11       Impact factor: 5.606

9.  Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study.

Authors:  Lisa M Noguchi; Barbra A Richardson; Jared M Baeten; Sharon L Hillier; Jennifer E Balkus; Z Mike Chirenje; Katherine Bunge; Gita Ramjee; Gonasagrie Nair; Thesla Palanee-Phillips; Pearl Selepe; Ariane van der Straten; Urvi M Parikh; Kailazarid Gomez; Jeanna M Piper; D Heather Watts; Jeanne M Marrazzo
Journal:  Lancet HIV       Date:  2015-07       Impact factor: 12.767

10.  Effect of Depot Medoxyprogesterone Acetate on Immune Functions and Inflammatory Markers of HIV-Infected Women.

Authors:  Adriana Weinberg; Jeong-Gun Park; Ronald Bosch; Alice Cho; Elizabeth Livingston; Fran Aweeka; Yoninah Cramer; D Heather Watts; Amneris E Luque; Susan E Cohn
Journal:  J Acquir Immune Defic Syndr       Date:  2016-02-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.